# US 2021/0171977 A1 · Synthetic promoters

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171977 A1
- Document ID: US20210171977A1
- Status: Published application
- Kind: A1
- Application number: 16/493,340
- Filed: 2018-03-13
- Published: 2021-06-10
- Earliest claimed: 2017-03-13
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Timothy Kuan-Ta Lu; Lior Nissim; Ming-Ru Wu
- Web page: https://patentgrep.com/patent/US20210171977A1

## CPC

- C12N 15/85: for animal cells
- A61K 35/763: Herpes virus
- C12N 15/86: Viral vectors
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N 2799/04: in vivo
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Aspects of the present disclosure provide synthetic promoters that are differentially modulated between certain diseased cells (e.g., cancer cells) and normal cells (e.g., non-cancer cells). These synthetic promoters are useful, for example, for targeted expression of therapeutic molecules in diseased cells.

## Claims

### Claim 1

An engineered nucleic acid comprising a promoter that comprises the following consensus sequence: TFBS-AGA-TFBS- TCG-TFBS-GAC-TFBS-CTA-TFBS-ACT-TFBS-TGC-TFBS-GTA-TFBS, wherein TFBS is a transcription factor binding site sequence of Table 5.

### Claim 2 (depends on 1)

The engineered nucleic acid of claim 1, wherein the activity of the promoter is increased in diseased cells relative to healthy cells.

### Claim 3 (depends on 1)

The engineered nucleic acid of claim 1, wherein the activity of the promoter is decreased in diseased cells relative to healthy cells.

### Claim 4 (depends on 2, 3)

The engineered nucleic acid of claim 2 or 3, wherein the diseased cells are selected from breast cancer cells, colon cancer cells, and ovarian cancer cells.

### Claim 5 (depends on 1, 2, 3, 4)

The engineered nucleic acid of any one of claims 1-4, wherein the promoter is operably linked to a nucleotide sequence encoding a therapeutic protein.

### Claim 6 (depends on 1, 2, 4)

The engineered nucleic acid of any one of claim 1, 2, 4, or 5, wherein the transcription factor binding site sequence comprises the following sequence: CCACGTGC (SEQ ID NO: 12265).

### Claim 7 (depends on 6)

The engineered nucleic acid of claim 6, wherein the promoter comprises the following sequence:
(SEQ ID NO: 12266)
CCACGTGCAGACCACGTGCTCGCCACGTGCGACCCACGTGCCTACCACG
TGCACTCCACGTGCTGCCCACGTGCGTACCACGTGCG.

### Claim 8 (depends on 1, 2, 4)

The engineered nucleic acid of any one of claim 1, 2, 4, or 5, wherein the transcription factor binding site sequence comprises the following sequence: TGCTGAGTCAGCA (SEQ ID NO: 12267).

### Claim 9 (depends on 8)

The engineered nucleic acid of claim 8, wherein the promoter comprises the following sequence:
(SEQ ID NO: 12268)
TGCTGAGTCAGCAAGATGCTGAGTCAGCATCGTGCTGAGTCAGCAGACT
GCTGAGTCAGCACTATGCTGAGTCAGCAACTTGCTGAGTCAGCATGCTG
CTGAGTCAGCAGTATGCTGAGTCAGCAG.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A cell comprising the engineered nucleic acid of any one of claims 1-9.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

An oncolytic virus comprising the engineered nucleic acid of any one of claims 1-9.

### Claim 12 (depends on 11)

The oncolytic virus of claim 11, wherein the oncolytic virus is an oncolytic herpes simplex virus.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12)

A method of delivering to a cell, optionally in a subject, the engineered nucleic acid of any one of claims 1-9 or the oncolytic virus of claim 11 or 12.

### Claim 14

An engineered nucleic acid comprising a promoter that comprises a nucleotide sequence identified by any one of SEQ ID NOS: 1-12263, or a nucleotide sequence at least 95% identical to a nucleotide sequence identified by any one of SEQ ID NOS: 1-12263.

### Claim 15 (depends on 14)

The engineered nucleic acid of claim 14, wherein the nucleotide sequence is identified by any one of SEQ ID NO: 1-49 or a nucleotide sequence at least 95% identical to any one of SEQ ID NO: 1-49.
